9.84
-0.33(-3.24%)
Currency In USD
| Previous Close | 10.17 |
| Open | 10.23 |
| Day High | 10.23 |
| Day Low | 9.71 |
| 52-Week High | 13.99 |
| 52-Week Low | 3.91 |
| Volume | 511,928 |
| Average Volume | 805,976 |
| Market Cap | 677.11M |
| PE | -4.07 |
| EPS | -2.42 |
| Moving Average 50 Days | 8.01 |
| Moving Average 200 Days | 7.88 |
| Change | -0.33 |
If you invested $1000 in EyePoint Pharmaceuticals, Inc. (EYPT) 10 years ago, it would be worth $229.91 as of July 16, 2025 at a share price of $9.84. Whereas If you bought $1000 worth of EyePoint Pharmaceuticals, Inc. (EYPT) shares 5 years ago, it would be worth $1,385.92 as of July 16, 2025 at a share price of $9.84.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
GlobeNewswire Inc.
Jun 16, 2025 11:00 AM GMT
WATERTOWN, Mass., June 16, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious retinal diseases, today announc
EyePoint Completes Enrollment in Pivotal Phase 3 LUGANO Trial of DURAVYU™ for Treatment of Wet Age-Related Macular Degeneration
GlobeNewswire Inc.
May 27, 2025 11:00 AM GMT
– Over 400 patients enrolled and randomized over a seven-month period, driven by strong physician and patient interest – – LUCIA pivotal Phase 3 trial continues rapid enrollment pace with 60% of patients randomized; enrollment completion expected in
EyePoint to Report First Quarter 2025 Financial Results on May 7, 2025
GlobeNewswire Inc.
Apr 30, 2025 11:00 AM GMT
WATERTOWN, Mass., April 30, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today